enGene Holdings Inc.

ENGNW

Held by 9 specialist biotech funds

High Convergence

9 funds opened new positions. Next phase2 readout (EG-70 (phase 1)): Jun 2026.

BiotechnologyCEO: Ronald H. W. CooperIPO: 2022Website ↗

EnGene Holdings Inc., through its enGene, Inc. subsidiary, is a clinical-stage biotechnology company dedicated to advancing genetic medicines. These innovative therapies are designed for targeted delivery to mucosal tissues and other bodily organs. Its foremost developmental asset, EG-70 (detalimogene voraplasmid), represents a non-viral immunotherapy. This treatment is specifically aimed at patients with non-muscle invasive bladder cancer, specifically the carcinoma-in-situ (CIS) subtype, who have shown no response to Bacillus Calmette-Guérin (BCG) therapy. Established in 2023, the firm's operations are based in Saint-Laurent, Canada.

enGene Holdings Inc.

Signal Score

Fund Holdings

Position Trend

Catalysts

Activist Filings

Recent Insider Activity

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research